Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer

Oxaliplatin is one of the most commonly used chemotherapeutic agent for the treatment of various cancers, including gastric cancer. It has, however, a narrow therapeutic index due to its toxicity and the occur...

Source: Journal of Experimental and Clinical Cancer Research - August 19, 2021 Category: Cancer & Oncology Authors: Haiyong Zhang, Jing Wu, Jinqiu Yuan, Huafu Li, Yawei Zhang, Wang Wu, Wei Chen, Chunming Wang, Sijun Meng, Songyao Chen, Mingyu Huo, Yulong He and Changhua Zhang Tags: Research Source Type: research